|
Synonyms: BIW-8405 | Fasenra® | KHK4563 | MEDI-563
benralizumab is an approved drug (FDA (2017), EMA (2018))
Compound class:
Antibody
Comment: Benralizumab is a humanized, afucosylated mAb targeting the IL5Rα which is expressed by cells of the eosinophil lineage. The antibody is afucosylated (ie has fucose containing oligosaccharide side-chains removed) to improve structure, stability, and biological function.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB link. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: benralizumab |
| No information available. |
Summary of Clinical Use  |
| In November 2017, the US FDA approved benralizumab as an add-on maintenance treatment for patients with severe eosinophilic phenotype asthma (aged 12 years and older). EMA marketing approval is pending a final decision, with their Committee for Medicinal Products for Human Use (CHMP) having recommended marketing authorisation on 9th November 2017 [3]. Results from Phase 3 clinical trial NCT01914757 are published in [4]. Analysis of trial outcomes show that not all asthma patients will respond to benralizumab, but that in patients with high eosinophil counts (> 300 cells per μL) annual exacerbation rates were significantly reduced. These suggest that targeting the biologic to specific patient populations will provide most clinical benefit. Click here to view ClinicalTrials.gov's listing of current benralizumab trials. |
| Mechanism Of Action and Pharmacodynamic Effects |
| This antibody targets the interleukin 5 receptor alpha subunit (IL5RA; IL-5Rα) [5]. Antibody targeting of IL-5Rα depletes eosinophils in lung tissue and bone marrow, thereby reducing eosinophilic inflammation caused by allergen exposure [1,7]. |
